Bristol Myers Squibb’s Opdualag fails to meet primary endpoint in Phase 3 trial

Bristol Myers Squibb has announced that its Phase 3 RELATIVITY-098 clinical trial, designed to evaluate Opdualag (nivolumab and relatlimab-rmbw) for adjuvant melanoma treatment, failed to ... Read More